Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Epidermolysis Bullosa Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Epidermolysis Bullosa Pipeline Outlook Report [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Epidermolysis Bullosa Pipeline Report

* In July 2025, Castle Creek Biosciences, LLC. announced a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
* In July 2025, Krystal Biotech, Inc. announced a study (protocol NHS) for at least 12 weeks and that meet all other eligibility criteria receive weekly ophthalmic administration of Investigational product (IP), KB803 or placebo, for the first 12-week intervention period. During the second intervention period subjects will receive the alternative IP for an additional 12 weeks. IP will be administered in the home setting by a healthcare provider.
* DelveInsight's Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 21+ pipeline therapies for Epidermolysis Bullosa treatment.
* The leading Epidermolysis Bullosa Companies such as Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
* Promising Epidermolysis Bullosa Pipeline Therapies such as diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.

Learn how leading Epidermolysis Bullosa Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Epidermolysis Bullosa Clinical Trials Assessment [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Epidermolysis Bullosa Emerging Drugs Profile

* EB-101: Abeona Therapeutics

EB-101 is an autologous, engineered cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer with severe epidermal wounds that impact the length and quality of their lives. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce Type VII collagen that helps anchor the dermal and epidermal layers of the skin. In November 2024, Abeona Therapeutics' biologics license application (BLA) for prademagene zamikeracel (pz-cel; EB-101), an investigational autologous gene-corrected epidermal sheet therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), has been accepted for filing by the FDA. The agency has set the Prescription Drug User Fee Act (PDUFA) action date for the BLA for April 29, 2025.

* INM-755: InMed Pharmaceuticals

INM-755 is a cannabinol (CBN) cream intended as a topical therapy to treat symptoms associated with epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 (cannabinol) cream may help relieve hallmark EB symptoms, such as pain, inflammation, wound healing and itch, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Epidermolysis Bullosa.

* BM-3103: BioMendics

The company's lead product in development, BM-3103, is a patented topical gel. It is currently being studied in a Phase I/IIa trial for epidermolysis bullosa simplex, with additional indications in the pipeline. MTORX technology is an investigational platform encompassing therapeutic candidate, BM-3103.

The Epidermolysis Bullosa Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
* Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.

From early-stage research to late-phase Epidermolysis Bullosa Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Epidermolysis Bullosa Treatment Drugs [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Epidermolysis Bullosa Companies

Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.

Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Epidermolysis Bullosa Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Stay updated with the latest Epidermolysis Bullosa Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Epidermolysis Bullosa Pipeline Report

* Coverage- Global
* Epidermolysis Bullosa Companies- Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
* Epidermolysis Bullosa Pipeline Therapies- diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
* Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Epidermolysis Bullosa Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Epidermolysis Bullosa Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Epidermolysis bullosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* EB-101: Abeona Therapeutics
* Mid Stage Products (Phase II)
* INM-755: InMed Pharmaceuticals
* Early Stage Products (Phase I)
* Drug name: Company name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Epidermolysis bullosa Key Companies
* Epidermolysis bullosa Key Products
* Epidermolysis bullosa- Unmet Needs
* Epidermolysis bullosa- Market Drivers and Barriers
* Epidermolysis bullosa- Future Perspectives and Conclusion
* Epidermolysis bullosa Analyst Views
* Epidermolysis bullosa Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-pipeline-outlook-report-2025-key-20-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.